Dr. Jay Bradner
President of the Novartis Institutes for BioMedical Research
Jay Bradner is President of the Novartis Institutes for BioMedical Research (NIBR), the company’s innovation engine. He leads thousands of scientists at research sites around the world in an effort to discover life-changing medicines for patients.
Jay’s bold ambition is for NIBR to go after the highest hanging fruit in drug discovery, including targets previously deemed impossible to reach, or “undruggable.” To support this research, NIBR has invested in powerful approaches and technologies such as targeted protein degradation, molecular glues and CRISPR.
3
March 22, 2022
The Future of Cancer Medicine with Dr. Jay Bradner, President of Novartis Institutes for BioMedical Research
In the last 20 years or so, many new cancer treatments have emerged that provide greater precision and targeting of cancer cells.Today, we have a better understanding of the genetic components of cancer.Through novel technology and cutting-edge science, we’re now able to understand how the accumulation of molecular alterations in the genome leads to the coding of proteins that can promote uncontrolled cell division.New treatments are emerging at the genetic and molecular level, along with novel approaches to targeting the new microenvironment that cancers create.On this episode of Theory and Practice, we explore the future of cancer medicine, and there’s no better leader to turn to for that discussion than Dr. Jay Bradner. Since 2016, he’s been president of the Novartis Institutes for BioMedical Research, where he leads the discovery and development of life-changing therapies to benefit patients.Theory and Practice is a presentation of GV and Google AI.Th…
Guest: Dr. Jay Bradner